Identification of Novel Low-Density Neutrophil Markers Through Unbiased High-Dimensional Flow Cytometry Screening in Non-Small Cell Lung Cancer Patients.
CD226
CD36
CD41
CD61
high-dimensional flow cytometry
low-density neutrophils
non-small cell lung cancer (NSCLC)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
04
2021
accepted:
15
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
18
12
2021
Statut:
epublish
Résumé
Neutrophils have been described as a phenotypically heterogeneous cell type that possess both pro- and anti-tumor properties. Recently, a subset of neutrophils isolated from the peripheral blood mononuclear cell (PBMC) fraction has been described in cancer patients. These low-density neutrophils (LDNs) show a heterogeneous maturation state and have been associated with pro-tumor properties in comparison to mature, high-density neutrophils (HDNs). However, additional studies are necessary to characterize this cell population. Here we show new surface markers that allow us to discriminate between LDNs and HDNs in non-small cell lung cancer (NSCLC) patients and assess their potential as diagnostic/prognostic tool. LDNs were highly enriched in NSCLC patients (median=20.4%, range 0.3-76.1%; n=26) but not in healthy individuals (median=0.3%, range 0.1-3.9%; n=14). Using a high-dimensional human cell surface marker screen, we identified 12 surface markers that were downregulated in LDNs when compared to HDNs, while 41 surface markers were upregulated in the LDN subset. Using flow cytometry, we confirmed overexpression of CD36, CD41, CD61 and CD226 in the LDN fraction. In summary, our data support the notion that LDNs are a unique neutrophil population and provide novel targets to clarify their role in tumor progression and their potential as diagnostic and therapeutic tool.
Identifiants
pubmed: 34484199
doi: 10.3389/fimmu.2021.703846
pmc: PMC8414579
doi:
Substances chimiques
Antigens, CD
0
Biomarkers, Tumor
0
Neoplasm Proteins
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
703846Subventions
Organisme : Austrian Science Fund FWF
ID : DOC 31
Pays : Austria
Organisme : NCI NIH HHS
ID : P50 CA228944
Pays : United States
Informations de copyright
Copyright © 2021 Valadez-Cosmes, Maitz, Kindler, Raftopoulou, Kienzl, Santiso, Mihalic, Brcic, Lindenmann, Fediuk, Pichler, Schicho, Houghton, Heinemann and Kargl.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Leukoc Biol. 2011 Feb;89(2):311-7
pubmed: 21106641
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787
pubmed: 29617574
Arthritis Rheum. 1986 Nov;29(11):1334-42
pubmed: 2430586
J Immunol. 2010 Mar 15;184(6):3284-97
pubmed: 20164424
Mod Rheumatol. 2017 Jan;27(1):122-129
pubmed: 27171278
Lupus. 2016 Apr;25(4):407-11
pubmed: 26453665
J Immunol. 2020 Jul 1;205(1):56-66
pubmed: 32444390
Cell. 2012 Jul 6;150(1):165-78
pubmed: 22770218
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Clin Lab Med. 2007 Sep;27(3):453-68, v
pubmed: 17658402
PLoS One. 2014 Feb 13;9(2):e85696
pubmed: 24551035
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
Development. 2002 Apr;129(8):2003-13
pubmed: 11934866
J Clin Invest. 2014 Dec;124(12):5466-80
pubmed: 25384214
Clin Cancer Res. 2017 May 1;23(9):2346-2355
pubmed: 27799249
Oncotarget. 2016 May 10;7(19):27676-88
pubmed: 27050283
Ann Allergy Asthma Immunol. 2014 Dec;113(6):635-640.e2
pubmed: 25256681
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55
pubmed: 21081700
PLoS One. 2011;6(11):e27690
pubmed: 22110722
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
Lung Cancer. 2018 Nov;125:128-135
pubmed: 30429010
Theranostics. 2019 Jul 9;9(17):4893-4908
pubmed: 31410189
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Res. 2001 Jun 15;61(12):4756-60
pubmed: 11406548
Blood. 2013 May 30;121(22):4463-72
pubmed: 23564910
Sci Signal. 2009 May 26;2(72):re3
pubmed: 19471024
Cancer Cell. 2016 Jul 11;30(1):120-135
pubmed: 27374224
J Exp Med. 2005 Jun 6;201(11):1771-80
pubmed: 15939792
Clin Chest Med. 2020 Mar;41(1):1-24
pubmed: 32008623
Clin Exp Immunol. 2013 Oct;174(1):45-52
pubmed: 23701226
Autoimmunity. 2009 May;42(4):353-5
pubmed: 19811299
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E566-75
pubmed: 25624500
Blood. 2017 Mar 9;129(10):1343-1356
pubmed: 28053192
Cell Rep. 2015 Feb 3;10(4):562-73
pubmed: 25620698
PLoS One. 2012;7(11):e48939
pubmed: 23152825
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30
pubmed: 23602134
Cell Rep. 2015 Dec 29;13(12):2829-2841
pubmed: 26711347
J Leukoc Biol. 2012 Jan;91(1):167-81
pubmed: 21954284
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Cancer Cell. 2005 Mar;7(3):211-7
pubmed: 15766659
Blood Cells Mol Dis. 2002 Mar-Apr;28(2):260-74
pubmed: 12064921
FASEB J. 2020 Mar;34(3):4204-4218
pubmed: 31957112
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Crit Care Med. 2013 Mar;41(3):820-32
pubmed: 23348516
Arthritis Rheumatol. 2015 Jul;67(7):1922-32
pubmed: 25891759
Cell Rep. 2019 Jun 25;27(13):3902-3915.e6
pubmed: 31242422
Oncotarget. 2017 Jun 28;8(53):90969-90978
pubmed: 29207617
Cancer. 2012 Mar 15;118(6):1726-37
pubmed: 21953630
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Nat Immunol. 2016 Jun;17(6):666-676
pubmed: 27043410
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711
PLoS One. 2016 Apr 13;11(4):e0153567
pubmed: 27073889